Clinical Trial Detail

NCT ID NCT01659151
Title Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

melanoma

Therapies

Aldesleukin

Fludarabine

Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST